Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated during Part 1 (dose escalation), and Part 2 (expansion) of the study was not initiated. This study was voluntarily terminated due to a business decision not to proceed with the ISB 1302 asset, and not due to any safety issue.

Conditions

Breast Cancer

Interventions

BIOLOGICAL: ISB 1302 250 ng/kg
BIOLOGICAL: ISB 1302 325 ng/kg
BIOLOGICAL: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22
BIOLOGICAL: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22
BIOLOGICAL: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22
BIOLOGICAL: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22
BIOLOGICAL: ISB 1302 escalating doses,1200 ng/kg D15,22
BIOLOGICAL: ISB 1302 at the MTD and/or RP2D dose

Sponsor

Ichnos Sciences SA

Collaborators

[object Object]